FGFR4 kinase inhibitor

This page covers all FGFR4 kinase inhibitor drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting FGFR4.

Targets

FGFR4

Phase 3 pipeline (1)

• BAY3723113 · Bayer · Oncology
  BAY3723113 is a selective inhibitor of fibroblast growth factor receptor 4 (FGFR4) that blocks aberrant FGF/FGFR signaling in hepatocellular carcinoma and other cancers.

Patent intelligence

• fgfr4 kinase inhibitor patent landscape — aggregated cliff calendar, attackable patents, originator estates